STAT

MARCH 12, 2024

… Acadia Pharmaceuticals disclosed that its approved medicine called Nuplazid failed to improve the social and emotional symptoms of schizophrenia in a late-stage clinical trial , STAT tells us. The company does not intend to conduct any further clinical trials with Nuplazid. We enjoy the feedback.

260

260

Pharmaceutical Technology

APRIL 18, 2024

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma).

40

40

World Pharma News

MARCH 1, 2024

Cleveland Clinic researchers have discovered a key mechanism used by Kaposi's sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), to induce cancer.

89

89

LifeProNow

MARCH 24, 2023

March 23, 2023: “AstraZeneca’s Calquence (acalabrutinib), a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been conditionally approved in China for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. The median DOR was not reached.

Hospitals 130

Hospitals 130

Pharmaceutical Technology

FEBRUARY 7, 2024

Avadomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase I for Follicular Lymphoma.

75

75

European Pharmaceutical Review

OCTOBER 17, 2023

In final guidance , the National Institute for Health and Care Excellence (NICE) has recommended glofitamab as a new treatment option for advanced lymphoma. NICE noted that clinical trial evidence suggests that some patients given glofitamab attained complete remission with no signs or symptoms of cancer. Data showed that 35.2

105

105

European Pharmaceutical Review

OCTOBER 13, 2023

BeiGene’s anti-cancer treatment is indicated for adults with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior lines of systemic therapy. if approved in follicular lymphoma – [BRUKINSA] will become the BTK inhibitor with the broadest label in the EU,” stated Dr Mobasher.

Labelling 100

Labelling 100

LifeProNow

MAY 8, 2023

With Breyanzi, people in Europe living with relapsed or refractory DLBCL now have a differentiated CAR T cell therapy option earlier in the treatment paradigm that provides long-term clinical benefit,” said Anne Kerber, senior vice president, head of Cell Therapy Development, Bristol Myers Squibb. months vs. 2.3

Chemotherapy 130

Chemotherapy Adverse Reactions 130

European Pharmaceutical Review

DECEMBER 28, 2023

In this exclusive interview, Andreas Harstrick, the Chief Medical Officer of Affimed unveils the potential of innate cell engagers for treating lymphoma. How has the treatment landscape for lymphoma evolved over the past few years?

Immunity 84

Immunity Immunization Chemotherapy Medical Schools 84

European Pharmaceutical Review

JUNE 5, 2023

Ninety-four percent of advanced stage (3 or 4) classic Hodgkin lymphoma patients treated with nivolumab, a PD-1 checkpoint inhibitor plus AVD chemotherapy (N-AVD) had one-year progression-free survival (PFS), according to Phase III trial results.

Chemotherapy 86

Chemotherapy Immunity Immunization 86

European Pharmaceutical Review

SEPTEMBER 26, 2023

Resminostat (Kinselby) has been clinically proven to postpone disease progression, new data from one of the largest clinical trials in cutaneous T-cell lymphoma (CTCL) to date has revealed. Findings from the RESMAIN study of the maintenance therapy could significantly change clinical practice in advanced CTCL” A 97.6

Labelling 93

Labelling Drug Development 93

Pharmafile

DECEMBER 11, 2023

Daiichi Sankyo has announced results from the phase 2 VALENTINE-PTCL01 trial of Ezharmia (valemetostat tosilate), which demonstrated a clinically meaningful and durable response in patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL).

59

59

STAT

JANUARY 23, 2024

In letters to the companies, the agency explained it had identified adverse events and clinical trial reports describing T-cell malignancies. Food and Drug Administration is requiring several manufacturers of CAR-T cancer therapies to add a serious warning on the prescribing information , Reuters notes.

Hospitals 253

Hospitals 253

Pharmacy Times

SEPTEMBER 8, 2023

Correctly diagnosing specific follicular lymphomas and marginal zone lymphomas requires knowledge of the clinical context, including the site of involvement, age, and clinical presentation.

58

58

Pharmaceutical Technology

APRIL 18, 2024

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Non-Hodgkin Lymphoma.

40

40

STAT

JUNE 7, 2023

What did we learn from this year’s annual meeting of the American Society of Clinical Oncology? At ASCO, we got statistical proof that patients with B-cell lymphoma who got Yescarta, a CAR-T made by Gilead, lived longer. Earlier this year, one of the first children cured with this tech, Emily Whitehead, spoke at a STAT event.

Drug Development 242

Drug Development 242

Pharmaceutical Technology

JANUARY 4, 2024

CB-010 is under clinical development by Caribou Biosciences and currently in Phase I for Follicular Lymphoma.

69

69

Pharmaceutical Technology

DECEMBER 21, 2023

SGN-1 is under clinical development by Guangzhou Sinogen Pharmaceutical and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma).

40

40

European Pharmaceutical Review

APRIL 20, 2023

It has been nearly 20 years since a new treatment option has become available [for] newly diagnosed with diffuse large B-cell lymphoma [in the US]” The US Food and Drug Administration (FDA) has approved Polivy ® (polatuzumab vedotin-piiq) in combination with Rituxan ® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP). “It

Immunity 96

Immunity Immunization 96

World Pharma News

SEPTEMBER 6, 2023

Alecensa demonstrated a statistically significant and clinically meaningful improvement in DFS as adjuvant therapy in people with completely resected stage IB (tumour ≥4cm) to IIIA (UICC/AJCC 7th edition) anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).

Chemotherapy 89

Chemotherapy 89

Express Pharma

NOVEMBER 1, 2023

Immunoadoptive Cell Therapy (ImmunoACT)’s NexCAR19 (actalycabtagene autoleucel) chimeric antigen receptor T-cell (CAR-T) therapy was approved in October by the Central Drug Standards Control Organisation (CDSCO) of India for the treatment of relapsed or refractory (r/r) B-cell lymphomas and leukemia.

92

92

Pharmaceutical Technology

JUNE 27, 2022

Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for its CD19-directed chimeric antigen receptor (CAR) T cell therapy Breyanzi (lisocabtagene maraleucel) to treat relapsed or refractory large B-cell lymphoma (LBCL) in adult patients.

105

105

Pharmaceutical Technology

JANUARY 8, 2024

SYD-4228 is under clinical development by Byondis and currently in Phase I for Follicular Lymphoma.

52

52

Pharmaceutical Technology

JULY 7, 2023

AC-0676 is under clinical development by Accutar Biotechnology and currently in Phase I for Follicular Lymphoma.

75

75

European Pharmaceutical Review

FEBRUARY 8, 2023

Yescarta for blood cancer Yescarta is targeting expansions into the first line for diffuse large B-cell lymphoma (DLBCL) and second line for follicular lymphoma in 2030. It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7

Labelling 96

Labelling Compounding 96

European Pharmaceutical Review

OCTOBER 31, 2022

AbbVie has announced that the European Medicines Agency (EMA) has validated its Marketing Authorisation Application (MAA) for epcoritamab, a bispecific antibody (bsAb) for adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after more than two lines of systemic therapy, offering patients a potential new therapy option.

Labelling 90

Labelling 90

Pharmaceutical Technology

DECEMBER 26, 2023

NVG-111 is under clinical development by NovalGen and currently in Phase I for Mantle Cell Lymphoma.

52

52

Pharmaceutical Technology

FEBRUARY 8, 2024

Cemacabtagene ansegedleucel is under clinical development by Allogene Therapeutics and currently in Phase II for Primary Mediastinal B-Cell Lymphoma.

40

40

Pharmaceutical Technology

OCTOBER 26, 2023

NKTR-255 is under clinical development by Nektar Therapeutics and currently in Phase III for Diffuse Large B-Cell Lymphoma.

52

52

Pharmaceutical Technology

JUNE 16, 2023

Roche Group member Genentech has secured approval from the US Food and Drug Administration (FDA) for its Columvi (glofitamab-gxbm) to treat adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Columvi will be available in the US later this year.

59

59

pharmaphorum

SEPTEMBER 26, 2022

Japan’s Daiichi Sankyo has claimed its first worldwide approval for Ezharmia, a first-in-class dual EZH1 and EZH2 inhibitor for the treatment of patients with relapsed or refractory adult T-cell leukaemia/lymphoma (ATL). Another from Jiangsu Hengrui Medicine (SHR2554) is still in early-stage clinical development.

Chemotherapy 98

Chemotherapy Labelling 98

Pharmaceutical Technology

APRIL 3, 2023

Eisai and the National Cancer Center have signed an agreement to partner on investigator-initiated clinical research for the anti-cancer agent, tazemetostat (Tazverik Tablets 200 mg), based on the Patient-Proposed Healthcare Services system.

Hospitals 98

Hospitals 98

Pharmaceutical Technology

FEBRUARY 8, 2024

Cemacabtagene ansegedleucel is under clinical development by Allogene Therapeutics and currently in Phase II for Diffuse Large B-Cell Lymphoma.

40

40

Pharmaceutical Technology

FEBRUARY 8, 2024

Cemacabtagene ansegedleucel is under clinical development by Allogene Therapeutics and currently in Phase II for Marginal Zone B-cell Lymphoma.

52

52

Pharmaceutical Technology

MAY 19, 2023

Myeloid Therapeutics has raised $73m to support the continued clinical development of its lead cell therapy programme, MT-101, in Phase I/II trials for T cell lymphoma. The financing will help to fast-track the development of other in vivo programming candidates into clinical trials.

Labelling 98

Labelling 98

Pharmaceutical Technology

FEBRUARY 8, 2024

Cemacabtagene ansegedleucel is under clinical development by Allogene Therapeutics and currently in Phase II for Follicular Lymphoma.

40

40

European Pharmaceutical Review

NOVEMBER 22, 2022

The US Food and Drug Administration ( FDA ) has accepted priority review of AbbVie’s Biologics License Application of epcoritamab (DuoBody®-CD3xCD20), an investigational subcutaneous bispecific antibody (BsAb), for adults with relapsed/refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy.

Labelling 90

Labelling 90